Previous 10 | Next 10 |
DUBLIN, Ireland and TREVOSE, Pa., July 01, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced t...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than five years. This subset of the different portfolios I regularly analyze has now reached 162 weeks of public selections as part of this ongoing live forward-testing re...
DUBLIN, Ireland and TREVOSE, Pa., June 01, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced th...
DUBLIN, Ireland and TREVOSE, Pa., May 20, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced th...
DUBLIN, Ireland and TREVOSE, Pa., May 18, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced th...
Strongbridge Biopharma ( SBBP +7.3% ) completes enrollment in a Phase 3 clinical trial, LOGICS , evaluating Recorlev (levoketoconazole) in patients with Cushing syndrome , a metabolic disorder characterized by the excess production of the hormone cortisol. More news on: Strongbridge ...
We previously outlined the bull case for Strongbridge in our article on January 30 , after which the stock declined heavily throughout 1Q 2020. This occurred as major shareholder, Broadfin Capital, was in the process of closing its doors and selling its position, followed by pressure from the...
DUBLIN, Ireland and TREVOSE, Pa., May 11, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced th...
Strongbridge Biopharma plc (SBBP) Q1 2020 Earnings Conference Call May 6, 2020 8:30 AM ET Company Participants Lindsay Rocco - Elixir Health Public Relations John Johnson - Executive Chairman Fred Cohen - Chief Medical Officer Rob Lutz - Chief Financial Officer Conference C...
The following slide deck was published by Strongbridge Biopharma plc in conjunction with their 2020 Q1 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
Strongbridge Biopharma plc Company Name:
SBBP Stock Symbol:
NASDAQ Market:
Strongbridge Biopharma plc Website:
DUBLIN, Ireland and TREVOSE, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”) today announced that the High Court of Ireland (the "Court") has approved the previously announced proposed a...
DUBLIN, Ireland and TREVOSE, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “ Company ” or “ Strongbridge ”) today announced that the High Court of Ireland (the “ Court ”) has set the dat...
DUBLIN, Ireland and TREVOSE, Pa., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “ Company ” or “ Strongbridge ”) today announced that its shareholders have voted to approve the previously announced proposed ac...